Last Updated: 14/01/2025
Optimizing a deployable high efficacy malaria vaccine—OptiMalVax
Objectives
To make the best-ever malaria vaccine for Plasmodium falciparum;
- High efficacy
- Multi-stage
- Multi-antigen (up to eight!)
- Deployable
- Cost-effective
This study will:
- undertake clinical trials to assess the pre-erythrocytic, blood-stage and mosquito-stage components.
- use state-of-the art immunomonitoring, key functional assays of vaccine-induced immunogenicity, and pre-erythrocytic and blood-stage parasite challenges to demonstrate vaccine safety, immunogenicity and efficacy.
Radboud University Medical Center (RUMC), The Netherlands
Leiden University Medical Center (LUMC), The Netherlands
UPMC Paris Universitas, France
Wellcome Sanger Institute, United Kingdom
Statens Serum Institute (SSI), Denmark
James Cook University, Australia
PATH, United States
Medical Research Council (MRC) Unit The Gambia at the London School of Hygiene and Tropical Medicine, The Gambia
University of Lausanne (UNIL), Switzerland
Janssen Infectious Diseases and Vaccines, United States
Australian Institute of Tropical Health and Medicine (AITHM), Australia
Novavax, United States
IMAXIO, France
OptiMalVax is a Collaborative Project on malaria vaccine development funded by the European Union’s Horizon 2020 Programme and coordinated by the Jenner Institute at the University of Oxford.
A highly effective malaria vaccine against the causative parasite Plasmodium falciparum should help prevent half a million deaths from malaria each year.
New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible.
Leading malariologists, vaccine researchers and product developers will here collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates.
Jan 2017 — Dec 2021
Related Resources
